Farther Finance Advisors LLC Sells 1,392 Shares of UiPath Inc. (NYSE:PATH)

Farther Finance Advisors LLC decreased its stake in UiPath Inc. (NYSE:PATH) by 23.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,620 shares of the healthcare company’s stock after selling 1,392 shares during the period. Farther Finance Advisors LLC’s holdings in UiPath were worth $59,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in PATH. Allspring Global Investments Holdings LLC lifted its stake in UiPath by 819.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 19,209 shares of the healthcare company’s stock valued at $435,000 after purchasing an additional 17,120 shares during the last quarter. Empowered Funds LLC lifted its stake in UiPath by 10.5% in the 1st quarter. Empowered Funds LLC now owns 10,856 shares of the healthcare company’s stock valued at $246,000 after purchasing an additional 1,033 shares during the last quarter. Sei Investments Co. raised its stake in shares of UiPath by 51.7% during the first quarter. Sei Investments Co. now owns 69,016 shares of the healthcare company’s stock valued at $1,565,000 after acquiring an additional 23,529 shares during the last quarter. Russell Investments Group Ltd. raised its stake in shares of UiPath by 96.6% during the first quarter. Russell Investments Group Ltd. now owns 75,851 shares of the healthcare company’s stock valued at $1,720,000 after acquiring an additional 37,267 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of UiPath by 79.8% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 39,263 shares of the healthcare company’s stock valued at $890,000 after acquiring an additional 17,423 shares during the last quarter. Institutional investors own 62.50% of the company’s stock.

UiPath Trading Up 1.2 %

NYSE:PATH opened at $13.52 on Thursday. The stock has a market capitalization of $7.44 billion, a price-to-earnings ratio of -67.60 and a beta of 0.87. The firm has a fifty day simple moving average of $12.60 and a two-hundred day simple moving average of $13.48. UiPath Inc. has a 12 month low of $10.37 and a 12 month high of $27.87.

UiPath (NYSE:PATH) last released its quarterly earnings data on Thursday, September 5th. The healthcare company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.01. UiPath had a negative net margin of 8.13% and a negative return on equity of 3.98%. The firm had revenue of $316.00 million for the quarter, compared to analyst estimates of $303.69 million. During the same period last year, the firm earned ($0.09) earnings per share. The business’s quarterly revenue was up 10.0% compared to the same quarter last year. Equities analysts predict that UiPath Inc. will post -0.23 earnings per share for the current fiscal year.

Insider Buying and Selling at UiPath

In other UiPath news, CFO Ashim Gupta sold 47,671 shares of the firm’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $12.07, for a total value of $575,388.97. Following the transaction, the chief financial officer now directly owns 849,917 shares of the company’s stock, valued at approximately $10,258,498.19. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 22.37% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on PATH shares. Needham & Company LLC reaffirmed a “hold” rating on shares of UiPath in a research note on Wednesday, October 23rd. Bank of America raised their price target on shares of UiPath from $16.00 to $18.00 and gave the company a “neutral” rating in a research note on Friday, September 6th. Morgan Stanley reaffirmed an “equal weight” rating and set a $15.00 price target on shares of UiPath in a research note on Friday, September 6th. Barclays raised their price target on shares of UiPath from $14.00 to $15.00 and gave the company an “equal weight” rating in a research note on Friday, September 6th. Finally, Evercore ISI increased their price objective on shares of UiPath from $13.00 to $16.00 and gave the stock an “in-line” rating in a research report on Friday, September 6th. Sixteen investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, UiPath currently has a consensus rating of “Hold” and a consensus price target of $17.47.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.